title: Nutraceuticals as Lipid-Lowering Treatment in Pregnancy and Their Effects on the Metabolic Syndrome.
abstract: Maternal nutrition and lifestyle before and during pregnancy influence both mother and offspring's health and can be correlated with the metabolic syndrome in later life. Findings from animal and human studies indicate that nutrition during pregnancy has an important role in microbiological, metabolic, physiologic and immunologic development and homeostasis. A low nutritional intake in early pregnancy may represent a risk for adverse effects during pregnancy as well as on birth outcome. It seems that dietary supplementation with probiotics in perinatal period may represent safe and practical approach in dealing with the most common adverse pregnancy outcomes such as obesity and gestational diabetes. The SPRING (Study of Probiotics in the prevention of Gestational diabetes) will give important answers about potential benefits of probiotics in pregnant women who are obese and overweight and otherwise at the high risk for complications during pregnancy. Fish oil supplementation during the last trimester of pregnancy showed no effects on plasma lipids and lipoproteins in offspring, as well as on their adiposity. The effect of hypercholesterolemia during pregnancy on both mothers and child needs to be further investigated as it could have a biological role. The guidelines for the eventual clinical approach currently do not exist. Potential benefits of nutraceuticals on several metabolic parameters have been suggested. Limited evidence does not allow to draw final conclusions on preventive health strategies and dietary patterns that should be promoted during pregnancy. Further prospective and intervention studies are needed to establish it. Healthy lifestyle and dietary advice with appropriate supplements usage should be considered.
authors.forename: Tamima
authors.initials: T
authors.lastname: Al-Dughaishi
authors.forename: Dragana
authors.initials: D
authors.lastname: Nikolic
authors.forename: Fahad
authors.initials: F
authors.lastname: Zadjali
authors.forename: Khamis
authors.initials: K
authors.lastname: Al-Hashmi
authors.forename: Khalid
authors.initials: K
authors.lastname: Al-Waili
authors.forename: Manfredi
authors.initials: M
authors.lastname: Rizzo
authors.affiliation: Department of Clinical Biochemistry, Sultan Qaboos University Hospital, P.O. Box: 38, postal code 123, Muscat, Oman. k.alrasadi@gmail.com.
authors.forename: Khalid
authors.initials: K
authors.lastname: Al-Rasadi
mesh_terms: D000818:Animals; D016640:Diabetes, Gestational / Q000188:drug therapy / Q000453:epidemiology; D019587:Dietary Supplements; D005260:Female; D006801:Humans; D008055:Lipids / Q000037:antagonists & inhibitors* / Q000097:blood*; D024821:Metabolic Syndrome / Q000188:drug therapy* / Q000453:epidemiology / Q000378:metabolism; D009765:Obesity / Q000188:drug therapy / Q000453:epidemiology / Q000378:metabolism; D011247:Pregnancy / Q000187:drug effects* / Q000378:metabolism; D019936:Probiotics / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D008055:Lipids